Overview

The Therapeutic Goods Act 1989 (TGA) was enacted by the Commonwealth of Australia to regulate the supply and importation of therapeutic goods, ensuring they meet safety, quality, and efficacy standards. This Act addresses the need to regulate therapeutic goods comprehensively, thereby protecting public health by ensuring that these goods are of acceptable quality and do not pose undue risks. Enacted by the Australian Parliament, the TGA provides the framework for the regulation of therapeutic goods, aiming to ensure that such goods are appropriately assessed and monitored throughout their lifecycle. The Act facilitates the management of therapeutic goods by allowing for the issuance of consents under certain conditions, as evidenced by the Delegate's consent for specific therapeutic goods during the period between 26 October 2010 and 15 November 2010, subject to particular conditions aimed at maintaining public safety and product quality.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods within Australia, encompassing the control of the supply and importation of such goods. This Act provides the legislative framework for ensuring that therapeutic goods are of acceptable quality and safety for public use. The Act applies to both individuals and entities that engage in the manufacture, supply, importation, or distribution of therapeutic goods. These goods include medicines, medical devices, and other health-related products. The scope of the Act extends nationally across Australia, with the Commonwealth having overarching regulatory authority over therapeutic goods. While the Act provides broad coverage, there are certain exclusions and exemptions, such as for goods that are for personal use only and not intended for supply, as well as for research and clinical trials under specific conditions. The Act may also be extended or modified through subordinate legislation, which can include regulations and standards that further define the scope and application of the primary Act.

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989 (the Act) concern the consent given by a Delegate of the Secretary of the Department of Health and Ageing for the supply and importation of therapeutic goods under certain conditions. Between 26 October 2010 and 15 November 2010, consent was provided to Wyeth Consumer Healthcare Pty Ltd for the supply and importation of Centrum products, identified by their Australian Register of Therapeutic Goods number (ARTG No.), under specific conditions and for a defined period. The consent granted allows for the supply and importation of Centrum products without full compliance with certain clauses of the applicable standards, provided the specified conditions are met. The obligations imposed by the Act on Wyeth Consumer Healthcare Pty Ltd include adhering to the specified conditions under which consent was granted. For instance, the content of individual water-soluble vitamins in Centrum products must not be less than 90 per cent and not more than 150 per cent of the stated content, and the dissolution of riboflavin and iron must comply with the United States Pharmacopeia-National Formulary chapter <2040>. Furthermore, the minimum letter height on the bottle label of the 14 tablet pack must not be less than 1.3 mm. These obligations are designed to ensure that the therapeutic goods supplied meet certain quality and safety standards. Breach of the conditions specified in the consent or failure to meet the obligations imposed by the Act can lead to various consequences. The Therapeutic Goods Act 1989 provides for both civil and criminal penalties for non-compliance. Civil penalties can include fines and other monetary penalties, while criminal penalties can include imprisonment. The exact penalties depend on the severity and nature of the breach, as well as any other relevant circumstances. It is important for entities governed by the Act to ensure strict compliance with the conditions and obligations to avoid these consequences.